Trevi Therapeutics, Inc. (TRVI) Earnings Call Transcript & Summary

May 5, 2026

NASDAQ US Health Care Pharmaceuticals earnings 32 min

Earnings Call Speaker Segments

Jennifer Good

executive
#1

Good afternoon, and thanks for being here on our Q1 2026 earnings call and business update. With me on the line today are my colleagues Dr. James Cassella, who serves as our Chief Development Officer, Farrell Simon, our Chief Commercial Officer, and David Hastings, our Chief Financial Officer. Dave and I have a few opening remarks, though we'll keep them short since we have a substantial presentation coming this Thursday at our Investor and Analyst Day. Once we wrap up our quarter commentary, the team would be glad to take whatever questions you have. For the company, 2026 stands as a significant year of execution, and everyone here is concentrated on delivering. After the positive FDA meeting we held in the first quarter to align on our IPF-related chronic cough program, the team has completed the study protocols for our phase III trials and has been working hard to identify global sites for both pivotal studies; we anticipate launching the first of those two studies during this quarter, with the second one to follow in the second half of this year. Having reached alignment with the FDA at our end-of-phase II meeting, we now plan to submit a meeting request and protocol to the FDA to discuss our non-IPF interstitial lung disease, or non-IPF ILD-related chronic cough program. Our intention is to propose an adaptive phase II/III study that would confirm dose and powering assumptions within the phase II portion before rolling into one pivotal phase III study for approval. Should everything proceed as proposed to the FDA, we anticipate starting this trial in the second half of the year. This non-IPF ILD population will mirror the patient profile from our IPF trial, since it will enroll patients with established lung fibrosis and chronic cough. There are many synergies with our IPF studies, given that these non-IPF ILD patients are seen at the same care centers by the same pulmonologist. While we negotiate CDAs, contracts, and budgets for launching our IPF-related chronic cough trials, we have this trial within scope so we can move quickly once alignment with the FDA on the protocol is achieved. Lastly, for refractory chronic cough, we also anticipate starting a phase II-B parallel arm dose-ranging trial with three doses and placebo this quarter as well. The protocol is finalized and has been submitted to regulatory authorities. We are actively qualifying sites for this trial; it includes a sample size re-estimation, or SSRE, which will read out when 50% of the patients complete the trial and is designed to confirm powering assumptions and adjust the sample size if necessary. We expect the SSRE readout in the fourth quarter of this year. The last thing I want to mention is how our intellectual property portfolio is progressing. We hold global rights to our drug, and beyond the patents already granted, we're sharply focused on pursuing additional patent protection step by step. During this quarter, our key method-of-treatment patent covering IPF-related chronic cough was granted in Europe. That same patent was previously granted in the U.S., and it safeguards us out to 2039. This year we submitted further applications in the U.S. that, should they be granted, would push patent protection out to 2046. We'll continue to keep you posted as these incremental IP developments unfold. Before wrapping up, I'd like to flag two significant meetings taking place this month, and we hope to see plenty of you there. The first is our Investor and Analyst Day, happening this Thursday, May 7th, from 10:00 A.M. until 12:00 P.M. Eastern Time, with an optional lunch afterward in New York City. There, we intend to present specifics on the upcoming clinical trials, timelines we project for every one of our chronic cough programs, and talk through additional data we've generated while we keep examining the clinical trial data we already have. We'll also pass along commercial insights drawn from recent market research and get perspectives from KOLs. It ought to be a worthwhile event, and for anyone who can't make it, the webcast and slides will be posted afterward. Second, we'll have a strong presence at this year's American Thoracic Society, or ATS, meeting — all six of our submissions were accepted, whether for presentations or posters. We're also hosting an investor analyst event at ATS, where Jim and Dr. Philip Molyneaux, who serves as lead investigator on our CORAL trial, will give an overview and share the various data being presented at the conference. That gathering will be a lunch meeting on Monday, May 18th. If you're planning to be at ATS, please get in touch, since we'd be delighted to have you there. To wrap up, we're intent on carrying out our plan to become the leader in chronic cough, delivering therapy to these patients who lack good options, and along the way generating meaningful value for patients as well as our shareholders. I'll hand things over now to Dave for his comments, and after that we'll gladly take your questions. Dave?

David Hastings

executive
#2

Thank you, Jennifer, and hello everyone on the line this afternoon. Today I'll keep my comments brief and zero in on the financial measure that matters most to us — our cash on hand and how long that cash can carry us. As of the close of Q1 2026, we held roughly $172 million across cash equivalents and marketable securities. That figure leaves out the $162 million in net proceeds tied to our underwritten common stock offering, which wrapped up in April 2026. Reception to that offering was strong. We felt great about the robust backing and involvement from our existing stockholders, and we're thankful we could bring new investors into Trevi. On top of that, finishing this offering let us check off two key goals. First, we eliminated any financing overhang once we hit pivotal, high-value clinical endpoints. Second, we pushed our cash runway out to 2030. Woven into that runway projection is money to support our development efforts in patients suffering from IPF-related chronic cough, possibly all the way to FDA approval. Beyond that, we anticipate these funds will let the company pay for and disclose top-line results from the phase II-B study we have planned, and perhaps a phase III study that follows, for treating patients with non-IPF ILD-related chronic cough. It also covers the planned phase II-B study in patients with RCC. Our planned use of these funds additionally takes in pre-commercial work, though it excludes any costs tied to a commercial launch of Haduvio or to any other trials. Given all this, I feel we're now in a solid position to run our clinical trials with financing that carries us through crucial value inflection points. Operator, please go ahead and open the line for questions.

Roanna Ruiz

analyst
#3

Thanks. Good afternoon, all. I have a few questions. To start, I'm interested in knowing what you hope to achieve at the next FDA meeting regarding the protocol for your phase II-B trial in non-IPF ILD chronic cough. Could you say more about anything you think may be open for debate with the agency, as opposed to the more clear-cut items?

James Cassella

executive
#4

Hi, Roanna. Jim here. I appreciate you asking. In essence, the purpose of that meeting is to go over what we plan for the ILD program. We're going to hand in the complete phase II-B/III protocol so it can be reviewed, and we'll really lay out what we intend regarding an sNDA approach, meaning we'd seek approval based on that adaptive phase II/III design. There will be specifics regarding the patient population we're targeting, the way we plan to employ phase II to verify dose selection and settle on the dose that moves forward into phase III, and then bringing in the findings from that trial's phase II portion, along with the interim analysis, to verify our power assumptions and to support the phase III part.

Roanna Ruiz

analyst
#5

That makes sense. Just one more quick question. When we think about RCC phase II-B possibly expanding too, and advancing into a non-IPF ILD, could you speak a little to how you intend to juggle resources and set priorities, given that you've got so many genuinely compelling irons in the fire going forward?

James Cassella

executive
#6

Yeah. Sleep isn't something we're big fans of. Everything is under control on our end. This isn't the first occasion I've overseen several programs with a compact team. We draw on our in-house know-how; we've brought in a highly seasoned CRO, one I collaborated with going back to my previous NDA, and I've got many years of experience alongside them; that group is extremely close-knit. The vendors we've brought on board are genuinely there to back us across every one of our programs. My sense is we're well positioned to pull these things off. I have zero doubt that we possess the capabilities and the brainpower to accomplish these things. I've spent close to 40 years working with small companies. We understand how to allocate the resources needed to accomplish these things.

Jennifer Good

executive
#7

Jim, Roanna, one more thing from my side: roughly 10 hires have come on board since the phase II-B data came in. A highly seasoned pulmonologist joined us. Multiple clinical staff members have come aboard as well. For an organization our size, bringing in 10 individuals represents substantial recruitment. Our aim has been to grow in a fitting way so we can handle how demanding these studies have become.

Roanna Ruiz

analyst
#8

Yeah, that works. Appreciate it.

Jennifer Good

executive
#9

Thanks for asking.

Judah Frommer

analyst
#10

Hello everyone, and I appreciate the update and your willingness to answer our questions. We have a couple of things to ask. First, regarding competition in RCC, there's a P2X3 data release expected around the middle of the year. I'm wondering what your expectations are for how the market might shift for Haduvio depending on where that P2X3 result falls across the range of possible outcomes. Specifically, if the findings turn out to be surprisingly robust, how would that affect your prospects in RCC? And what impact might it have on getting patients enrolled in the RCC study? Thank you.

Jennifer Good

executive
#11

Farrell, could you handle the question about the competitive landscape, and then Jim can address the enrollment piece.

Farrell Simon

executive
#12

Judah, thanks for asking that. So, as we examine the field we compete in, particularly with camlipixant, whose data should arrive shortly — within a couple of weeks — our hope is that it performs well, correct? This is a sizable population of patients whose needs aren't met, with nothing approved to treat them, and it's certainly an area that can accommodate several kinds of approaches. Our central and peripheral mechanism of action gives us a clear point of difference, and on Thursday at the Investor Day, what we'll walk you through is precisely how that sets us up to win. I'll hand it over. On the other hand, I'd add that should camlipixant fail in that area, then I believe we'd need to examine where we stand competitively; our efficacy is quite strong, so we'll see what the phase II-B results show and what commercial opportunity awaits. The unmet need remains large. Patients are out there waiting for us. I'll pass it to Jim.

James Cassella

executive
#13

Yes. So, when it comes to getting people enrolled, you know, the investigators for that trial are already on board. Everyone's quite enthusiastic. We've got plenty of patients we can reach. No matter what goes on in that setting, the investigators we've got for this study give us solid backing, and they genuinely mention that many patients are both available and eager to join our trial. I believe our distinct mechanism, the results we've presented, how robust the data is that we've put out there, remains truly the main thing fueling the desire to take part in our study.

Jennifer Good

executive
#14

By the point they finally secure approval, our phase II-B will already be finished; perhaps that becomes something to handle as a phase III matter. Yeah, I appreciate the question.

Judah Frommer

analyst
#15

Thanks. Perhaps at a broader conceptual level regarding the ILDs — as additional inhaled-formulation medications are either coming into or reaching later stages in the IPF and PPF areas, coughing tends to be a frequent adverse event across many of those studies. I'm simply wondering how you believe the chance for Haduvio might be affected by a greater number of inhaled treatments within the IPF and PPF areas. Thanks.

Jennifer Good

executive
#16

Judah, this comes up often. Clearly, what we're addressing is a more systemic form of chronic cough. Whether the hypersensitization is connected to patients using those inhaled therapies and whether it could be calmed down is something that will need to be understood as time goes on. I do believe these various treatments are beneficial. They will shape the market. They provide choices. We are able to sit alongside every one of them. That's the reason Jim has been occupied with these DDI studies. Whether we might assist with the cough caused by their method of delivery is something that will have to be found out.

Judah Frommer

analyst
#17

Thanks.

Jennifer Good

executive
#18

Yeah. Thank you.

Alexa Deemer

analyst
#19

Hey everyone, thanks for letting me ask, and congratulations on such a strong quarter. Regarding the guidance on data readouts for the program that's coming up, that kicks off in 2027's second half. I simply wanted to check whether any additional data updates are anticipated that we might see prior to then. Thank you.

Jennifer Good

executive
#20

Well, there's the SSRE — the sample size re-estimation — at the RCC trial's midpoint. That ought to come through during this year's fourth quarter; whether enrollment plays out as hoped remains to be seen, and that's the timeline we're aiming for. In my view, that readout for the RCC trial will be quite informative. Apart from that, our present plan remains the second half of 2027. I'd like to back up what Jim said. I've also been attending quite a few of these investigator meetings. Our programs are drawing a great deal of interest and attention. The team, I believe, is positioning us to succeed here. As we progress through the trials, we'll keep updating all of you — things are certainly advancing well.

Alexa Deemer

analyst
#21

Awesome. Thank you.

Jennifer Good

executive
#22

Thanks, Alexa.

John Todaro

analyst
#23

Afternoon, everyone. John here, filling in for Serge right now. Appreciate you taking our questions. We've got a few for you. To start, I may be getting a bit ahead of things, but with SSRE and RCC both scheduled to arrive later this year, I'm wondering which key checkpoints you'll be watching for throughout that analysis. My guess is it could end up resembling the IPF one that was conducted in phase II; if more patients turn out to be needed, I'm just curious how you'd anticipate that playing out. Second, regarding the IP side, as I understand it, you hold patents issued through 2039. I'm curious whether, and in what areas, you'd aim to grow that portfolio before Haduvio potentially reaches commercialization. Thanks a lot.

Jennifer Good

executive
#24

Right. Jim, would you like to handle the SSRE?

James Cassella

executive
#25

Right. The SSRE works the same way as what we did in CORAL. At the midpoint, it checks for 80% conditional power. Should the figures come in under that — should conditional power at that stage fall below 80% — then we'll increase the size proportionally, and just as in the CORAL design, if futility shows up, that gets picked up as well. That lands somewhere in the 30%-40% range. I'd say conditional power is really the thing you'd expect out of CORAL carrying over to this study, and we'll report whether we need to keep things as they are or go bigger.

Jennifer Good

executive
#26

Okay, regarding your second question, John, on intellectual property: right now we find ourselves in a rather intriguing spot. The foundational core patents have been granted in IPF, and at this point we have a solid sense of how our label is going to shape up. So we've begun pursuing the various label-enablement patents. These are the things we're focusing on tied to the label, such as the final titration schedule, such as the way dosing gets adjusted for food or hepatic impairment. Jim is conducting quite a few different phase I studies. Those studies typically yield a great deal for IP. Given that we now hold a fairly broad method-of-treatment patent covering treating cough and these indications, our aim at this stage is to start constructing around the label. We will keep patents and applications active, so that when development work is finished and we discover new information, we can file incremental IP related to those findings. When this drug ultimately reaches the market, our objective would be to have multiple patents surrounding the original base patent.

John Todaro

analyst
#27

Excellent, I really appreciate the detail.

Jennifer Good

executive
#28

Thanks.

Ryan Deschner

analyst
#29

Ryan, thanks for asking. There's some really compelling dyspnea information that will be presented at ATS in Orlando later this month. In terms of a quality of life measure for IPF chronic cough patients, how big a deal do you believe dyspnea is, and how much does modulating dyspnea potentially matter for the RCC and non-IPF ILD indications? We'll circle back.

Farrell Simon

executive
#30

Farrell here — Ryan, appreciate the question. In fact, we've conducted quite a bit of research alongside physicians and payers on this topic. When considering the three most frequent complaints among these patients, be it IPF or ILD, dyspnea sits within that group. Cough, dyspnea, and fatigue make up those top three; our commercial thesis isn't altered by it, yet it can certainly add to how quickly the product gets taken up, and also, I believe, to patient adoption, since it will assist them with more than just one of the things they deal with and how those things affect them.

Jennifer Good

executive
#31

And discussions with payers, correct?

Farrell Simon

executive
#32

Discussions with payers. It's going to be useful when talking to payers; it will assist in demonstrating extra value.

Ryan Deschner

analyst
#33

Understood. What steps will you take in the RCC clinical program to try to keep placebo effects down? In the IPF chronic cough and non-IPF ILD indications, is a high potential placebo also that much of a worry?

James Cassella

executive
#34

Hi Ryan, this is Jim. I'd say we've got strong results out of our CORAL study in the IPF population. The placebo response came in at under 20%, which I think was what we anticipated. My sense is also that within chronic cough, this is likely among the better-behaved groups, and I'd expect to see roughly that going forward. In the RCC space, I believe there's precedent suggesting the placebo response may be somewhat more variable and may cover a wider range. In this trial, we're taking every measure to truly account for the factors that can feed into a placebo response. Much of that, I think, comes down to running an extremely well-controlled trial, and that's what we're striving to do. At the recommendation of certain experts in the RCC space, we're also building in a placebo run-in period, with the aim of blunting any response there. The thinking behind that is to look for stability near the lower end of cough response. Those elements are being incorporated, and naturally, there are the general rules of thumb I carry over from my CNS background, where placebo response is always a major worry — it really comes down to trial conduct and ensuring you don't create false expectations, don't overpromise, and similar things, since those can add to the overall placebo response.

Ryan Deschner

analyst
#35

Thanks a lot.

Debanjana Chatterjee

analyst
#36

Hello, and thanks for taking my question. Congratulations on everything that's been accomplished. As we look toward ATS, which developments are the most exciting ones we should be anticipating? I've got a quick follow-up as well.

Jennifer Good

executive
#37

Jim and I are both going to be there. The two of us are looking at one another. Jim, why don't you take this one. You're the author on a bunch of them.

James Cassella

executive
#38

Hey, Deb. I believe there are a few exciting developments to share regarding the oral presentation Dr. Phil Molyneaux will be delivering. What I mean is, that will include some fresh sub-analyses coming out of our CORAL study. I also expect there will be a number of compelling presentations and posters focused on cough bouts — that's our cough bout analysis covering both CORAL and RIVER. This came up before, but I'd say our breathlessness data, which Don Mahler is presenting — and he truly is one of the leading experts in this area — is going to make for a really exciting poster, one that shares that initial analysis demonstrating some benefit when it comes to the breathlessness side of things. I'd say those are the highlights, and I think they genuinely bring some new information into the data flow for us.

Debanjana Chatterjee

analyst
#39

Thanks for that detail. One more quick question. Naturally, I realize FVC isn't an endpoint you're going after, but since you'll be tracking the IPF patients for at least 52 weeks in the phase III program, do you think any trends might show up there? Even if it's essentially a safety endpoint?

James Cassella

executive
#40

FVC is something we're tracking. It's measured at baseline; we have it across the whole 52-week window. So we'll be in a position to examine whatever shows up. What we're aiming for differs greatly from a typical IPF trial, since FVC fluctuates a lot, and that, I believe, is what determines how large those trials need to be. The only thing I can guarantee is that we'll report whatever we observe.

Debanjana Chatterjee

analyst
#41

Thanks.

William Wood

analyst
#42

Appreciate you fielding our questions, and congratulations on a strong quarter. I'm mainly wondering about the upcoming P2X3 readout from the peer group. Is there anything particular you'll be watching for in that study, whether it turns out positive or negative, that you believe could sharpen what you take to the FDA or improve what you learn for your own trials?

Jennifer Good

executive
#43

Let me just dive in here, Jim, and feel free to add anything. Thanks for asking, William. I don't believe there is. P2X3s have essentially had to pursue this route involving the heaviest coughers, placebo run-ins, and heavily adjudicated indications. We've generated data showing our drug works broadly in IPF chronic cough and refractory chronic cough across varying cough counts. My sense is we can be far less picky about who enrolls and how we obtain results. Naturally, we'll be curious about the placebo effect and the way they've handled it, but those studies were upsized. The larger one got upsized on two occasions, and that's invariably difficult, I think; they're also dealing with a considerably tighter response. We'll take a look. We're interested. I share Farrell's view. I hope they generate some benefit for patients; they're steering toward roughly a 15%-20% placebo-adjusted change in their calls. We'd anticipate our drug performing much better. Our aim really is to be best in class among the most refractory patients for our drug. As Farrell noted, it's more about how we position the drug and where we head, but I'd say nothing here truly affects our program; our phase II-B will teach us more than their phase III data likely will.

William Wood

analyst
#44

Got it.

Jennifer Good

executive
#45

Yep.

William Wood

analyst
#46

That helps. Just one small thing to add quickly. Regarding how we should be thinking about your upcoming KOL event and also at ATS — is there anything particular the FDA might want, in terms of what they'd guide for your chronic cough trials related to non-IPF ILD, that you plan to bring up at these events, which would really help support the push forward and/or specific patient subsets, as you get ready to meet with them during the second half? Thanks for taking our questions.

Jennifer Good

executive
#47

We've got an ILD expert based in the U.S., Dr. Toby Maher, who heads a large ILD center. He will be speaking there. He has to Zoom in since he has clinic. Among the subjects we've requested he address is whether, in his view, an IPF patient and an ILD patient are the same or not when it comes to cough. You'll hear directly from one of the experts here. Toby has been part of our program since the start. He is quite familiar with our drug. In fact, he was on our FDA call with us. On Thursday, you'll get some independent perspectives from truly one of the leading voices in the ILD field.

William Wood

analyst
#48

That's helpful. Thank you.

Jennifer Good

executive
#49

Yeah. Thank you, William.

Kaveri Pohlman

analyst
#50

All right. Yes, good evening, and thank you for letting me ask. I'd like to piggyback on what you said earlier regarding the design of the phase II-B RCC trial. My question is how you're contemplating bringing in a patient population that's truly addressable so the program gets fully de-risked, especially since so many patients are expected to have prior P2X3 antagonist exposure in the real world. Then, more broadly and at a high level, it seems like attention keeps building around development progress in IPF and non-IPF ILD, clearly alongside the ongoing work in RCC. In light of the shifting treatment landscape, how are you weighing the relative opportunity among those indications? And which key challenges in RCC still have to be tackled before its full potential can be realized? Thank you.

Jennifer Good

executive
#51

That's quite a few questions to pull apart. Let me begin from a strategy standpoint. From the start, Trevi has been guided by an IPF approach, then layered with an ILD-led approach, largely because of how we've set up our commercial strategy: specialty, high pricing, specialty sales force — that has always been where our focus sat. As the RCC competitive landscape kind of eroded and basically little remained, some experts approached us and asked whether we would please test our drug in RCC. We did, and the data came back very strong. So there's certainly a commitment to RCC, though it sits as the third leg of the stool here. As for the variability in the program and the P2X3 responders — anything to add, Jim?

James Cassella

executive
#52

So, I believe what you're getting at is whether individuals who've previously been exposed to P2X3 could potentially enroll in our study. What I'd say is, the crucial factor is whether they satisfy the eligibility criteria and have discontinued their P2X3 for a suitable duration — they still need to fulfill the study's entry conditions, and if so, they're eligible to participate. We're looking for patients with a range of backgrounds; as we know, this is a refractory condition, and patients have attempted numerous treatments and may or may not have had success with a P2X3, but provided they satisfy our entry criteria, they'll be enrolled. To me, that doesn't really set them apart from any other therapy they might have undergone previously. They'll need to fulfill the eligibility conditions requiring them to be off a P2X3 for a specified period.

Kaveri Pohlman

analyst
#53

Got it. Thank you.

Jennifer Good

executive
#54

Thank you, Kaveri.

Jennifer Good

executive
#55

Thanks for being with us on today's call, and we hope to see a lot of you later in the week and over the course of this month. Thank you.

Operator

operator
#56

This concludes today's conference call. Thank you for attending. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Trevi Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Trevi Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Trevi Therapeutics, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.